BR112021019446A2 - Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial - Google Patents

Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial

Info

Publication number
BR112021019446A2
BR112021019446A2 BR112021019446A BR112021019446A BR112021019446A2 BR 112021019446 A2 BR112021019446 A2 BR 112021019446A2 BR 112021019446 A BR112021019446 A BR 112021019446A BR 112021019446 A BR112021019446 A BR 112021019446A BR 112021019446 A2 BR112021019446 A2 BR 112021019446A2
Authority
BR
Brazil
Prior art keywords
urothelial carcinoma
fgfr
treatment
tyrosine kinase
kinase inhibitors
Prior art date
Application number
BR112021019446A
Other languages
English (en)
Inventor
Elena Santiago-Walker Ademi
Narayan Avadhani Anjali
Elizabeth O'HAGAN Anne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021019446A2 publication Critical patent/BR112021019446A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial. a presente invenção refere-se a métodos de tratamento de carcinoma urotelial em um paciente, compreendendo a avaliação de uma amostra biológica do paciente quanto à presença de pelo menos duas alterações genéticas do receptor do fator de crescimento de fibroblastos (fgfr) e o tratamento do paciente com um inibidor de fgfr. também são aqui descritos métodos de tratamento de carcinoma urotelial em um paciente com pelo menos duas alterações genéticas do receptor do fator de crescimento de fibroblastos (fgfr), compreendendo a administração de um inibidor de fgfr.
BR112021019446A 2019-03-29 2020-03-27 Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial BR112021019446A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166428 2019-03-29
EP19188971 2019-07-30
PCT/US2020/025166 WO2020205493A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
BR112021019446A2 true BR112021019446A2 (pt) 2021-11-30

Family

ID=70296138

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019446A BR112021019446A2 (pt) 2019-03-29 2020-03-27 Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial

Country Status (14)

Country Link
US (1) US20220054484A1 (pt)
EP (1) EP3946341A1 (pt)
JP (1) JP2022527189A (pt)
KR (1) KR20210145211A (pt)
CN (1) CN113645974A (pt)
AU (1) AU2020253827A1 (pt)
BR (1) BR112021019446A2 (pt)
CA (1) CA3130460A1 (pt)
IL (1) IL286729A (pt)
JO (1) JOP20210266A1 (pt)
MA (1) MA55522A (pt)
MX (1) MX2021011926A (pt)
SG (1) SG11202109902SA (pt)
WO (1) WO2020205493A1 (pt)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
RU2425041C2 (ru) 2005-05-23 2011-07-27 Новартис Аг Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN113957146A (zh) 2014-09-26 2022-01-21 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
SG11202109902SA (en) 2021-10-28
AU2020253827A1 (en) 2021-09-30
KR20210145211A (ko) 2021-12-01
WO2020205493A1 (en) 2020-10-08
JOP20210266A1 (ar) 2023-01-30
JP2022527189A (ja) 2022-05-31
CA3130460A1 (en) 2020-10-08
MA55522A (fr) 2022-02-09
IL286729A (en) 2021-10-31
MX2021011926A (es) 2021-11-03
EP3946341A1 (en) 2022-02-09
CN113645974A (zh) 2021-11-12
US20220054484A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
BR112019025056A2 (pt) Inibidores de fgfr2 para o tratamento de colangiocarcinoma
BR112017013599A2 (pt) composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras.
CY1119451T1 (el) Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
BR112018010933A2 (pt) anticorpos multiespecíficos
MX2022004937A (es) Inhibidores de las cinasas raf.
MX2018005461A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
PH12020550195A1 (en) Use of p38 inhibitors to reduce expression of dux4
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
BR112022021136A2 (pt) Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
BR112018001438A2 (pt) expressão de fgfr e suscetibilidade a um inibidor de fgfr
BR112019026577A8 (pt) Compostos aminotiazol como inibidores de proteína quinase
Islam et al. Epidermal growth factor is a critical regulator of the cytokine IL‐33 in intestinal epithelial cells
CR20230500A (es) Métodos para inhibir ras
Park et al. The indolinone MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells without the inhibition of VEGFR-3 phosphorylation: involvement of the RhoA and Akt/GSK3β signaling pathways
Rizaner et al. Riluzole: Anti‐invasive effects on rat prostate cancer cells under normoxic and hypoxic conditions
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
BR112021019446A2 (pt) Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial
BR112021019203A2 (pt) Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial
BR112019008622A2 (pt) método para tratar uma condição
BR112022015827A2 (pt) Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco
CL2023003126A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa